119 related articles for article (PubMed ID: 2108885)
21. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group.
Sharifi R; Soloway M
J Urol; 1990 Jan; 143(1):68-71. PubMed ID: 2104638
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women.
Filicori M; Flamigni C; Cognigni G; Dellai P; Arnone R; Falbo A; Capelli M
J Clin Endocrinol Metab; 1993 Jul; 77(1):130-3. PubMed ID: 8325935
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
[TBL] [Abstract][Full Text] [Related]
24. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
[TBL] [Abstract][Full Text] [Related]
25. Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals.
Ogawa Y; Okada H; Heya T; Shimamoto T
J Pharm Pharmacol; 1989 Jul; 41(7):439-44. PubMed ID: 2570847
[TBL] [Abstract][Full Text] [Related]
26. Persistent suppression of the pituitary-gonadal system in female rats by three-month depot injectable microspheres of leuprorelin acetate.
Okada H; Doken Y; Ogawa Y
J Pharm Sci; 1996 Oct; 85(10):1044-8. PubMed ID: 8897268
[TBL] [Abstract][Full Text] [Related]
27. A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.
Dowsett M; Mehta A; Mansi J; Smith IE
Br J Cancer; 1990 Nov; 62(5):834-7. PubMed ID: 2123115
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
Santen RJ; Warner B
Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
[TBL] [Abstract][Full Text] [Related]
29. Depot leuprolide acetate dosage for sexual precocity.
Parker KL; Baens-Bailon RG; Lee PA
J Clin Endocrinol Metab; 1991 Jul; 73(1):50-2. PubMed ID: 1904452
[TBL] [Abstract][Full Text] [Related]
30. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
[TBL] [Abstract][Full Text] [Related]
31. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
[TBL] [Abstract][Full Text] [Related]
32. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
Kappy M; Stuart T; Perelman A; Clemons R
J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
[TBL] [Abstract][Full Text] [Related]
33. Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma.
Santen RJ; Demers LM; Max DT; Smith J; Stein BS; Glode LM
J Clin Endocrinol Metab; 1984 Feb; 58(2):397-400. PubMed ID: 6420439
[TBL] [Abstract][Full Text] [Related]
34. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
35. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of (D-Leu6)-des Gly-NH2 10-LHRH ethylamide against prostatic cancer.
Yamanaka H; Makino T; Yajima H; Saruki K; Shida K
Prostate; 1985; 6(1):27-34. PubMed ID: 3918298
[TBL] [Abstract][Full Text] [Related]
37. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
[TBL] [Abstract][Full Text] [Related]
38. Depot leuprolide acetate for treatment of precocious puberty.
Parker KL; Lee PA
J Clin Endocrinol Metab; 1989 Sep; 69(3):689-91. PubMed ID: 2503536
[TBL] [Abstract][Full Text] [Related]
39. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
Berges R; Bello U
Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.
Wong SL; Lau DT; Baughman SA; Fotheringham N; Menchaca D; Garnick MB
J Clin Pharmacol; 2004 May; 44(5):495-502. PubMed ID: 15102870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
